Atualmente, existe uma grande necessidade médica por enxertos vasculares de pequeno calibre (< 6 mm), que possam ser utilizados em cirurgias de reconstrução vascular. Nesse trabalho, dois tipos de biomateriais vasculares foram desenvolvidos pela técnica de electrospinning: biomateriais de policaprolactona (PCL) e biomateriais de poli(carbonato de trimetileno – co – ácido lático) (PTMCLLA). Os biomateriais de PCL foram funcionalizados com heparina e com VEGF (PCL/Hep/VEGF). Os biomateriais de PTMCLLA foram desenvolvidos a partir de três razões de carbonato de trimetileno/ ácido lático: 20/80, 30/70 e 40/60. Os biomateriais de PCL apresentaram taxa de degradação lenta e alta elasticidade. A funcionalização dos biomateriais preveniu a coagulação do sangue e também favoreceu o crescimento de células-tronco mesenquimais (CTMs) e de células progenitoras endoteliais (CPEs) nessas estruturas. A análise de PCR demonstrou que o VEGF adsorvido aos biomateriais não foi suficiente para diferenciar as CTMs em células endoteliais. O cultivo das CPEs sobre os biomateriais aumentou a expressão de VE-caderina e a presença de VEGF nas estruturas manteve o nível de expressão de CD31 e CD34 nessas células. Após essas análises, os biomateriais de PCL/Hep/VEGF foram fabricados em formato tubular. As CPEs foram semeadas no lúmen do biomaterial, através de biorreatores de parede rotatória (BPR), e mantidas em cultivo, por biorreatores de perfusão (BP). O BPR favoreceu a distribuição homogênea das CPEs na parede luminal dos biomateriais enquanto que o BP estimulou seu crescimento e otimizou seu metabolismo energético. Os biomateriais produzidos a partir dos copolímeros de PTMCLLA 30/70 e 40/60 exibiram uma alta flexibilidade. Porém, os biomateriais de PTMCLLA 40/60 tiveram um grande enrugamento. Os biomateriais de PTMCLLA 30/70 suportaram a adesão e o crescimento de CTMs, de CPEs e de células musculares lisas. Os resultados obtidos no presente estudo demonstram que biomateriais de PCL/Hep/VEGF apresentam características físico-químicas compatíveis para o uso vascular. Ainda, previnem a formação de trombos em sua superfície e propiciam o desenvolvimento da camada endotelial em seu lúmen. Os biomateriais de PTMCLLA 30/70 exibem alta flexibilidade e suportam o desenvolvimento de células vasculares e de células-tronco mesenquimais. De acordo com esses resultados, é possível concluir que biomateriais de PCL/Hep/VEGF e de PTMCLLA 30/70 são candidatos promissores para aplicação como enxertos vasculares. / Currently, there is a great medical need for small caliber vascular grafts (<6 mm), which can be used in vascular replacement surgeries. In this work, two types of vascular biomaterials were developed by the electrospinning technique: biomaterials of polycaprolactone (PCL) and biomaterials of poly(trimethylene carbonate-co-L-lactide) (PTMCLLA). PCL biomaterials were functionalized with heparin and VEGF (PCL / Hep/VEGF). The PTMCLLA biomaterials were developed from three ratios of trimethylene carbonate/lactide: 20/80, 30/70 and 40/60. The PCL biomaterials presented a slow degradation rate and high elasticity. The functionalization of the biomaterials prevented the blood from clotting and also favored the growth of mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) in these structures. PCR analysis demonstrated that VEGF adsorbed by the biomaterials was not sufficient to differentiate the MSCs into endothelial cells. The cultivation of CPEs on the biomaterials increased their expression of VE-cadherin and the presence of VEGF in the structures maintained the cell expression of CD34 and CD31. After these analyzes, the PCL/Hep/VEGF biomaterials were produced in a tubular geometrical form. The CPEs were seeded into their lumen by rotating bioreactors (RB) and maintained in culture by perfusion bioreactors (PB). The RB favored the homogeneous distribution of the CPEs in the luminal wall of the biomaterials while the BP stimulated their growth and optimized their energetic metabolism. The biomaterials produced from the PTMCLLA 30/70 and 40/60 copolymers exhibited high flexibility. However, the PTMCLLA 40/60 biomaterials exhibited substantial wrinkling. The PTMCLLA 30/70 biomaterials supported the adhesion and growth of MSCs, CPEs and smooth muscle cells. This study has demonstrated that PCL/Hep/VEGF biomaterials have physicochemical characteristics compatible with vascular use. Furthermore, they prevent thrombus formation on their surfaces and promote the development of the endothelial layer in their lumen. Biomaterials of PTMCLLA 30/70 exhibit high flexibility and support the development of vascular and mesenchymal stem cells. According to these results, it can be concluded that PCL/Hep/VEGF and PTMCLLA 30/70 biomaterials are promising candidates for use as vascular grafts.

Le virus de la maladie de Borna (BDV) est un virus persistant dans le système nerveux central responsable de troubles du comportement chez l’animal et possiblement chez l’homme. En utilisant des cellules progénitrices neurales humaines, des travaux antérieurs à mon arrivée au laboratoire ont montré que BDV altère la neurogenèse humaine. Les objectifs de ma thèse étaient d’identifier les déterminants viraux responsables de cette altération et de caractériser les mécanismes moléculaires impliqués. Nous avons montré que la phosphoprotéine (P) et la nucléoprotéine (N), mais pas la protéine X, induisent une inhibition spécifique de la neurogenèse humaine, la genèse des astrocytes n’étant pas altérée. Ensuite, focalisant notre étude sur P, nous avons montré qu’elle affectait particulièrement la genèse des neurones GABAergiques. La caractérisation moléculaire a ensuite révélé une diminution de l’expression de gènes impliqués dans la spécification (ApoE et Noggin) et dans la maturation (SCG10/Stathmin2 et TH) neuronale. En conclusion, nos résultats démontrent, pour la première fois, qu’une protéine virale perturbe la neurogenèse GABAergique humaine, un processus connu pour être dérégulé dans certaines maladies psychiatriques. Ils améliorent ainsi notre compréhension de la pathogenèse de ce virus persistant et de son rôle possible dans les maladies psychiatriques chez l’homme. / Borna disease virus (BDV) is a persistent neurotropic virus causing neurobehavioral disorders in animals and possibly humans. Using human neural progenitor cells, it had been shown, before my arrival in the laboratory, that BDV induces an alteration in human neurogenesis. Here, we aimed at identifying the viral determinants involved in BDV-induced impairment of neurogenesis and at characterizing the underlying molecular mechanisms. We demonstrated that the phosphoprotein (P) and the nucleoprotein (N), but not the X protein, reduce neurogenesis. Focusing on the role of P, we evidenced an impairment of GABAergic neurogenesis. Then, seeking for the molecular mechanisms responsible for P-induced inhibition of neurogenesis, we showed that it induces a decrease in the expression of cellular factors involved in either neuronal specification (ApoE, Noggin) or maturation (SCG10/Stathmin, TH). Thus, in this study, we demonstrated for the first time that a viral protein is capable of inhibiting GABAergic neurogenesis, a process that is dysregulated in some psychiatric diseases. Our results improve our understanding of the pathogenesis of this persistent neurotropic virus and of its possible role in psychiatric disorders.

No description available.

Gliomas are the most common primary tumors of the central nervous system believed to arise from glial cells. Invasive growth and inherent propensity for malignant progression make gliomas incurable despite extensive treatment. I have developed a life-like orthotopic glioma model and used this and other in vivo models to study basic mechanisms of glioma development and treatment. Previous studies had indicated that experimental gliomas could arise from glial stem cells and astrocytes. The present thesis describes the making and characterization of a novel mouse model, Ctv-a, where gliomas are induced from oligodendrocyte progenitor cells (OPCs). Our study shows that OPCs have the capacity to give rise to gliomas and suggests in light of previous data that the differentiation state of the cell of origin affects tumor malignancy. CDKN2A encodes p16INK4a and p14ARF (p19Arf in mouse) commonly inactivated in malignant glioma. Their roles in experimental glioma have been extensively studied and both proteins have tumor suppressor functions in glial stem cells and astrocytes. Here, we demonstrate that p19Arf only could suppress gliomagenesis in OPCs while p16Ink4a had no tumor suppressive effect. Functional DNA repair is pivotal for maintaining genome integrity, eliminating unsalvageable cells and inhibiting tumorigenesis. We have studied how RAD51, a central protein of homology-directed repair, affected experimental glioma development and have found that expression of RAD51 may protect against genomic instability and tumor development. Angiogenesis, the formation of new blood vessels from pre-existing ones, is a central feature of malignant progression in glioma. Antiangiogenic treatment by inhibition of vascular endothelial growth factor receptor signaling is used in the clinic for treatment of some cancers. We have investigated the effect of an alternative antiangiogenic protein, histidine-rich glycoprotein (HRG), on glioma development and found that HRG could inhibit the formation of malignant gliomas and completely prevent the formation of glioblastoma.

En aquesta Tesi, un nou biomaterial de disseny composat per seqüències peptídiques repetitives i amfifíliques, que per autoensamblatge forma xarxes de nanofibres (i hidrogels), AcN-RADARADARADARADA-CONH2, s´ha utilitzat com a anàleg de la matriu extracel·lular per al manteniment, proliferació i diferenciació cel·lular. Aquest pèptid s'ha funcionalititzat amb motius biològicament actius procedents de proteïnes de la matriu extracel·lular incloent laminina-1 i colàgen IV. El scaffold peptídic autoensamblant RAD16-I i els seus derivats biològicament actius s´han caracteritzat i provat utilitzant diferents sistemes cel·lulars com pot ser les cèl·lules d'aorta humanes (HAEC), hepatocits madurs i la línea progenitora de fetge (Lig-8). La proteòlisi d'aquest pèptid s'ha avaluat utilitzant tripsina com a enzim proteolític, i els fragments resultants s'han analitzat per MALDI-TOF i AFM. Així mateix, la segona generació de biomaterials basats en el RAD16-I s'ha provat tant amb HAEC com amb hepatocits madurs. Amb aquests sistemes hem demostrat que el desenvolupament d'una matriu biomiètica reforça, a la vegada que manté, les funcions específiques de cada teixit. En particular, els resultats obtinguts en diferenciació, proliferació i manteniment de la funció cel·lular utilitzant pèptids sintètics autoensamblants són comparables amb els resultats que s'obtenen utilitzant matrius biològiques (Colàgen I i Matrigel). Això indica que els nostres anàlegs de la matriu extracel·lular poden substituir als materials naturals, i suggereix l'ús d'aquests materials intel·ligents amb capacitat instructiva en aplicacions terapèutiques. Així mateix s'ha provat que l'ús d'aquests pèptids auto-ensamblants és eficient en la construcció d'un nínxol de cèl·lules mare. Hem sigut capaços de controlar la cinètica cel·lular (de simètrica a assimètrica) induint diferenciació funcional, a la vegada que es mantenia una petita proporció de cèl·lules no diferenciades. Aquests resultats indiquen clarament que hem sigue capaços d'obtenir un nínxol on cèl·lules primitives (Lig-8) es diferencien adquirint funcions d'hepatocits madurs. Hem desenvolupat una plataforma de biomaterials que es podrien utilitzar per la funcionalització amb innumerables biomolècules amb capacitat d'induir processos biològics com la diferenciació, proliferació i funció metabòlica. Aquests biomaterials, preveiem que tindran un gran impacte a l'àrea terapèutica i biología regenerativa. / En esta Tesis, un nuevo biomaterial de diseño compuesto por secuencias peptídicas repetitivas y amfifílicas que por autoensamblaje forma redes de nanofibras (e hidrogeles), AcN-RADARADARADARADA-CONH2 (RAD16-I), se ha utilizado como análogo de la matriz extracelular para el mantenimiento, proliferación y diferenciación celular. Este péptido se ha funcionalizado con motivos biológicamente activos procedentes de proteínas de la matriz extracelular incluyendo laminina-1 y colágeno IV. El scaffold peptídico autoensamblante RAD16-I y sus derivados biológicamente activos se han caracterizado y probado utilizando diferentes sistemas celulares como puede ser células endoteliales de aorta humanas (HAEC), hepatocitos maduros y la línea progenitora de hígado Lig-8. La proteólisis de este péptido se ha evaluado utilizando tripsina como enzima proteolítico, y los fragmentos resultantes se han analizado por MALDI-TOF y AFM. Asimismo, la segunda generación de biomateriales basados en el RAD16-I se ha probado tanto con HAEC como hepatocitos maduros. Con estos sistemas hemos demostrado que el desarrollo de una matriz biomimética refuerza a la vez que mantiene las funciones específicas de cada tejido. En particular, los resultados obtenidos en diferenciación, proliferación y mantenimiento de la función celular utilizando los péptidos sintéticos auto-ensamblantes son comparables con los resultados que se obtienen usando matrices biológicas (Colágeno I y Matrigel). Esto indica que nuestros análogos de la matriz extracelular pueden reemplazar a los materiales naturales, y sugiere el uso de estos materiales inteligentes con capacidad instructiva en aplicaciones terapéuticas. Asimismo, se ha probado que el uso de estos péptidos auto-ensamblantes es eficiente en la construcción de un nicho de células madre. Hemos sido capaces de controlar la cinética celular (de simétrica a asimétrica) induciendo diferenciación funcional, a la vez que se mantenía una pequeña proporción de células no diferenciadas. Estos resultados indican claramente que hemos sido capaces de obtener un nicho donde células primitivas (Lig-8) se diferencian adquiriendo funciones de hepatocitos maduros. Hemos desarrollado una plataforma de biomateriales que se podrían utilizar para la funcionalización con innumerables biomoléculas con capacidad de inducir procesos biológicos como la diferenciación, proliferación y función metabólica. Estos biomateriales preveemos que tendrán un gran impacto en el área terapéutica y biología regenerativa. / In this Thesis, a new designed biomaterial made out of short repetitive amphiphilic peptide sequence AcN-RADARADARADARADA-CONH2 (RAD16-I) that self-assembles forming nanofiber networks (hydrogel scaffold) has been used as synthetic extracellular matrix analog for cell maintenance, proliferation and differentiation. This peptide has been functionalized with biological active motifs from extracellular matrix proteins including laminin-1 and collagen IV. The prototypic self-assembling peptide scaffold RAD16-I and its biologically active derivatives have been characterized and tested using several cellular systems such as human aortic endothelial cells (HAEC), mature hepatocytes and a putative liver progenitor cell line, Lig-8. The proteolysis of the peptide RAD16-I has been evaluated using trypsin as a proteolytic enzyme and the resulting fragments have been analyzed by MALDI-TOF and AFM. Moreover the second generation of RAD16-I-based biomaterials have been tested using HAEC and mature hepatocytes. With these systems we have shown that the development of a biomimetic matrix enhances as well as maintain tissue-specific functions. In particular, the results obtained in cell differentiation, proliferation and maintenance of cell function using the synthetic self-assembling peptide matrices, are comparable with the results obtained using natural biological matrices counterparts (Collagen-I and Matrigel). This indicates that our extracellular matrix analogs can replace the use of naturally-derived materials and suggests the use of these smart biomaterials with instructive capacity for cells in therapeutics. Moreover, the use of the self-assembling peptide RAD16-I in the recreation of a stem-cell niche proved to be highly efficient. We were able to control stem-cell kinetics (from symmetric to assymetric) inducing functional differentiation while maintaining a small proportion of undifferentiated cells. This striking results clearly indicate that we were able to obtain a stem-cell niche where primitive cells (Lig-8) undergo differentiation acquiring mature hepatic functions. We have developed a biomaterial platform that can be used for functionalization with innumerable biomolecules, with capacity to induce biological processes like differentiation, control of proliferation, metabolic function, etc. These biomaterials will have a strong impact in therapeutics and regenerative biology.

Thesis (Ph.D.)--Indiana University, 2009. / Title from screen (viewed on February 2, 2010). Department of Biochemistry and Molecular Biology, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): Mervin C. Yoder, Jr., David A. Ingram, Jr., Lawrence A. Quilliam, Mark D. Pescovitz. Includes vitae. Includes bibliographical references (leaves 171-194).

Τα επισωματικά αυτο-αναπαραγώμενα συστήματα αποτελούν υποσχόμενα εναλλακτικά οχήματα γονιδιακής μεταφοράς για εφαρμογές της γονιδιακής θεραπείας. Η πρόσφατη κατανόηση της ικανότητας των αλληλουχιών S/MAR να διαμεσολαβούν την επισωματική διατήρηση γενετικών στοιχείων επέτρεψε την ανάπτυξη ενός πρότυπου κυκλικού επισωματικού φορέα που λειτουργεί χωρίς να κωδικοποιεί πρωτεΐνες ιϊκής προέλευσης. Σε αυτή τη μελέτη, διερευνήθηκε για πρώτη φορά η δυνατότητα αυτού του φορέα, pEPI-eGFP, να μεσολαβεί γονιδιακή μεταφορά σε κυτταρικές σειρές προγονικών αιμοποιητικών κυττάρων καθώς και σε πρωτογενή ανθρώπινα κύτταρα και, κυρίως, σε ανθρώπινα προγονικά αιμοποιητικά κύτταρα. Δείχνουμε ότι ο φορέας pEPI-eGFP διατηρείται επισωματικά και υποστηρίζει παρατεταμένη έκφραση του γονιδίου αναφοράς eGFP, ακόμα και χωρίς πίεση επιλογής, στην ανθρώπινη κυτταρική σειρά K562, καθώς και σε πρωτογενείς ανθρώπινους ινοβλάστες. Αντίθετα, στην κυτταρική σειρά ερυθρολευχαιμίας ποντικού MEL, η έκφραση της eGFP αποσιωπάται μέσω αποακετυλίωσης ιστονών, παρά την επισωματική διατήρηση του φορέα. Προγονικά αιμοποιητικά κύτταρα με κλωνογόνο ικανότητα, προερχόμενα από αίμα ομφάλιου λώρου, διαμολύνονται αποτελεσματικά με το φορέα μέσω ηλεκτροδιάτρησης. Ημιστερεές αποικίες προερχόμενες από διαμολυσμένα CD34+ κύτταρα διατηρούν το φορέα και εκφράζουν eGFP. Μετά από 4 εβδομάδες ο φορέας διατηρείται επισωματικά σε περίπου 1% των θυγατρικών κυττάρων. Τα αποτελέσματά μας αποδεικνύουν για πρώτη φορά ότι ένα πλασμίδιο βασιζόμενο σε μια αλληλουχία S/MAR μπορεί να λειτουργεί ως σταθερό επιίσωμα σε πρωτογενή ανθρώπινα κύτταρα και, ιδιαίτερα, σε προγονικά αιμοποιητικά κύτταρα, υποστηρίζοντας παρατεταμένη έκφραση του διαγονιδίου. Η μελέτη αυτή αναδεικνύει τη χρησιμότητα του συστήματος αυτού για τους σκοπούς της γονιδιακής θεραπείας. Παράλληλα, καταδεικνύει τους στόχους στους οποίους πρέπει να επικεντρωθεί η μελλοντική έρευνα προς την κατεύθυνση της βελτίωσής του. / Episomally maintained self-replicating systems present attractive alternative vehicles for gene therapy applications. Recent insights into the ability of chromosomal scaffold/matrix attachment regions (S/MARs) to mediate episomal maintenance of genetic elements cloned in cis allowed the development of a small circular episomal vector that functions independently of virally encoded proteins. In this study, we investigated the potential of this vector, pEPI-eGFP, to mediate gene transfer in hematopoietic progenitor cell lines as well as in primary human cells and, importantly, in human hematopoietic progenitor cells. pEPI-eGFP was episomally maintained and conferred sustained eGFP expression even in nonselective conditions in the human cell line, K562, as well as in primary human fibroblast-like cells. In contrast, in the murine erythroleukemia cell line, MEL, transgene expression was silenced through histone deacetylation, despite the vector’s episomal persistence. Hematopoietic semisolid cell colonies derived from transfected human cord blood retained the vector and expressed eGFP. After 4 weeks, the vector was maintained in approximately 1% of progeny cells. Our results provide the first evidence that a S/MAR-based plasmid can function as a stable episome in primary human cells, supporting long-term transgene expression. The present study constitutes a proof of principle for the utility of this system in gene therapy applications and points at targets for future improvements.

No description available.

No description available.

No description available.